GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Short Interest

KLTO (Klotho Neurosciences) Short Interest


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Klotho Neurosciences's Short Interest

For the Biotechnology subindustry, Klotho Neurosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Klotho Neurosciences's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Short Interest falls into.


;
;

Klotho Neurosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Short Interest
Comparable Companies
GTBP PHIO AEON ACUT APM DRMA SIGY CELZ CYCN SILO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Website
https://www.klothoneuro.com
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.